⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes
globenewswire.com
PFE
LLY
MGNX
LGND
$28+ Billion Cancer Supportive Care Products Market Outlook Report, 2030
globenewswire.com
JNJ
MRK
ABBV
ABT
NVS
GSK
AMGN
TEVA
JAGX
LLY
New Nature-Published Research Reviews How Metabolic Dysfunction May Be Core Driver in Psychiatric Diseases
businesswire.com
LULU
AZN
LLY
Insilico Medicine Announces Global R&D Collaboration with Lilly
prnewswire.com
LLY
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
prnewswire.com
LLY
Remedy Meds GLP-1 Weight Loss 2026: Pricing, the FDA Compounding Shakeup, and What to Know Before You Commit to a Monthly Plan
accessnewswire.com
LLY
NVO
Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players
globenewswire.com
AMGN
BMY
LLY
JNJ
PFE
MRK
ZWS
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
prnewswire.com
LLY
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online — 2026 Search Trends and Publicly Available Pricing Information Context
globenewswire.com
LLY
Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
globenewswire.com
ABBV
AZN
BIIB
BMY
GSK
LLY
MRK
NVS
SNY
TEVA
UCB